We are separately advising Genetron and the special committee of its board on the transaction

Davis Polk is advising Genetron Holdings Limited and, separately, the special committee of the board of directors of Genetron in connection with the going-private acquisition of Genetron by a consortium consisting of Sizhen Wang, co-founder, chairman of the board of directors and chief executive officer of Genetron, certain funds affiliated with CICC, Wuxi Guolian and certain other investors. The going-private acquisition implies an equity value of Genetron of approximately $126 million. The transaction is subject to the approval of the shareholders of Genetron, regulatory filings and other customary closing conditions and is expected to close in the first quarter of 2024.

Genetron is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. It has developed a comprehensive product and service portfolio that covers the full cycle of cancer care, from early screening to diagnosis and treatment recommendations to continuous monitoring and continuous care.

The Davis Polk corporate team representing the special committee of Genetron includes partner Li He and registered foreign lawyer Michael Zhuoran Xu. Representing Genetron, the Davis Polk corporate team includes partner Xuelin (Steve) Wang and registered foreign lawyer Xin (Sheen) Xu. All members of the Davis Polk team are based in the Hong Kong office.

Copy link to share post